tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hypophosphatemia D017674 1 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Retrognathia D063173 1 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Axelrod D et al. Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients. 2005 Am. J. Transplant. pmid:15888050
Reyes J et al. Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). 2005 Am. J. Transplant. pmid:15888051
Knoop C et al. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. 2005 Am. J. Transplant. pmid:15888057
Kandaswamy R et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis. 2005 Am. J. Transplant. pmid:15888064
Cavadas PC et al. Bilateral trans-humeral arm transplantation: result at 2 years. 2011 Am. J. Transplant. pmid:21521475
Xu H et al. The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. 2014 Am. J. Transplant. pmid:24472192
Qazi Y et al. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data. 2017 Am. J. Transplant. pmid:27775865
Egli A et al. Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. 2010 Am. J. Transplant. pmid:20840474
Zafrani L et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. 2009 Am. J. Transplant. pmid:19538494
Touzot M et al. Renal transplantation in HIV-infected patients: the Paris experience. 2010 Am. J. Transplant. pmid:20840478
Krämer BK et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. 2010 Am. J. Transplant. pmid:20840480
Trunečka P et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. 2010 Am. J. Transplant. pmid:20840481
Wang Q et al. Biodegradable microsphere-loaded tacrolimus enhanced the effect on mice islet allograft and reduced the adverse effect on insulin secretion. 2004 Am. J. Transplant. pmid:15084166
Schubert M et al. Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. 2004 Am. J. Transplant. pmid:15084173
Budde K et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. 2014 Am. J. Transplant. pmid:25278376
O'Grady JG et al. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. 2007 Am. J. Transplant. pmid:17109723
Böhmig GA et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. 2007 Am. J. Transplant. pmid:17109725
Budde K et al. Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. 2010 Am. J. Transplant. pmid:20121745
Hanto DW et al. Intraoperative administration of inhaled carbon monoxide reduces delayed graft function in kidney allografts in Swine. 2010 Am. J. Transplant. pmid:20977633
Al-Massarani G et al. Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. 2008 Am. J. Transplant. pmid:18925903
Frassetto LA and Benet LZ Pharmacogenomics and transplantation: where are we? 2004 Am. J. Transplant. pmid:15147415
MacPhee IA et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. 2004 Am. J. Transplant. pmid:15147425
Artz MA et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. 2004 Am. J. Transplant. pmid:15147428
Hamdy AF et al. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. 2005 Am. J. Transplant. pmid:16162204
Kaufman DB et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. 2005 Am. J. Transplant. pmid:16162205
Schold JD The burden of proof in the design of early phase clinical trials. 2013 Am. J. Transplant. pmid:23802723
Chisholm-Burns MA et al. Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. 2013 Am. J. Transplant. pmid:23819827
Troppmann C et al. Impact of portal venous pancreas graft drainage on kidney graft outcome in simultaneous pancreas-kidney recipients reported to UNOS. 2004 Am. J. Transplant. pmid:15023146
Willicombe M et al. Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. 2011 Am. J. Transplant. pmid:21299828
Muthusamy AS et al. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. 2008 Am. J. Transplant. pmid:18828772
Pirenne J et al. Tolerance of liver transplant patients to strenuous physical activity in high-altitude. 2004 Am. J. Transplant. pmid:15023147
Heisel O et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. 2004 Am. J. Transplant. pmid:15023151
Srinivas TR et al. The noninferiority trial: don't don't do it. 2010 Am. J. Transplant. pmid:21087412
Senior PA et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. 2005 Am. J. Transplant. pmid:16095517
Kohnle M et al. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. 2006 Am. J. Transplant. pmid:16433776
Larson TS et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. 2006 Am. J. Transplant. pmid:16468960
Vitko S et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. 2006 Am. J. Transplant. pmid:16468962
Luan FL et al. Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. 2008 Am. J. Transplant. pmid:18786231
Woywodt A et al. Different preparations of tacrolimus and medication errors. 2008 Am. J. Transplant. pmid:18786238
Servais A et al. Interstitial fibrosis evolution on early sequential screening renal allograft biopsies using quantitative image analysis. 2011 Am. J. Transplant. pmid:21672152
Levi Z et al. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. 2007 Am. J. Transplant. pmid:17229076
Ogawa T et al. Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. 2007 Am. J. Transplant. pmid:17229077
Miriuka SG et al. mTOR inhibition induces endothelial progenitor cell death. 2006 Am. J. Transplant. pmid:16796720
Ryan CM and Swanson DP clinical research, innovative practice and IRB review: identifying and respecting boundaries. 2007 Am. J. Transplant. pmid:17331113
Levy G et al. REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. 2014 Am. J. Transplant. pmid:24456049
Triñanes J et al. Deciphering Tacrolimus-Induced Toxicity in Pancreatic β Cells. 2017 Am. J. Transplant. pmid:28432716
Ciancio G et al. Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. 2012 Am. J. Transplant. pmid:22946986
Jacobson PA et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. 2012 Am. J. Transplant. pmid:22947444
Pallet N et al. Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. 2016 Am. J. Transplant. pmid:26990694
Miller LW Cardiovascular toxicities of immunosuppressive agents. 2002 Am. J. Transplant. pmid:12392286